Cart
sales@molnova.com
Lacutamab
CAS No. 2187368-16-5
Lacutamab( —— )
Catalog No. M36888 CAS No. 2187368-16-5
Lacutamab (IPH 4102) is a potent and selective humanized anti-KIR3DL2 antibody.Lacutamab has potential anticancer activity for the study of leukemia and lymphoma.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 613 | In Stock |
|
| 10MG | 938 | In Stock |
|
| 25MG | 1454 | In Stock |
|
| 50MG | 1841 | In Stock |
|
| 100MG | 2595 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameLacutamab
-
NoteResearch use only, not for human use.
-
Brief DescriptionLacutamab (IPH 4102) is a potent and selective humanized anti-KIR3DL2 antibody.Lacutamab has potential anticancer activity for the study of leukemia and lymphoma.
-
DescriptionLacutamab (IPH4102) is a humanized monoclonal antibody (mAb) directed against the immune receptor molecule KIR3DL2, produced by recombinant technology in CHO cells. Lacutamab can be used in research of cutaneous T-cell lymphoma.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2187368-16-5
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Van Der Weyden C, et, al. IPH4102, a monoclonal antibody directed against the immune receptor molecule KIR3DL2, for the treatment of cutaneous T-cell lymphoma. Expert Opin Investig Drugs. 2018 Aug;27(8):691-697.?
molnova catalog
related products
-
Furimazine
Furimazine is an imidazopyrazinone substrate. NanoLuc (Nluc) paired with Furimazine produced 2.5 million-fold brighter luminescence in mammalian cells relative to Oluc-19 with Coelenterazine.
-
β I probe
β I probe
-
Sisunatovir HCl
Sisunatovir HCl is an orally available inhibitor of the RSV-F protein that has exhibited potent efficacy against a panel of clinical isolates of RSV-A and RSV-B viruses in vitro.
